Craif focuses on the research and development of next-generation diagnostic technologies, particularly for early detection and personalized medicine for cancer and other diseases
Craif focuses on the research and development of next-generation diagnostic technologies, particularly for early detection and personalized medicine for cancer and other diseases. Their flagship product, miSignal®, is a non-invasive cancer risk testing service based on urinary microRNA analysis.